Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06463028 · ClinicalTrials.gov registry record · Phase 2
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by Faeth Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 18
- Study locations
NCT06463028: Recruiting Phase 2 study of Endometrial Cancer, sponsored by Faeth Therapeutics.
NCT06463028 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Faeth Therapeutics. The registered enrollment target is 40 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06463028, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Faeth Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Primary Outcome
Defined as the proportion of participants with measurable disease at baseline who have confirmed complete response (CR) or partial response (PR).
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Sapanisertib
- DRUG Serabelisib
Study Locations (18)
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Florida Cancer Specialists, North - St. Petersburg
- Florida Cancer Specialists, East - West Palm Beach
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California, San Francisco (UCSF) - San Francisco
New York
- Women's Cancer Care Associates, LLC - Albany
- Memorial Sloan Kettering Cancer Center - New York
Oregon
- Oncology Associates of Oregon, P.C. - Eugene
- Northwest Cancer Specialists, P.C. - Portland
Pennsylvania
- Alliance Cancer Specialists, PC - Doylestown
- West Penn Hospital - Pittsburgh
Texas
- Texas Oncology - West Texas - El Paso
- Texas Oncology - Gulf Coast - The Woodlands
Maryland
- Maryland Oncology Hematology, P.A. - Brandywine
Minnesota
- Minnesota Oncology Hematology, P.A. - Maple Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
What NCT06463028 shows while recruiting
NCT06463028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.
NCT06463028 lists 18 locations in 11 states (Florida, California, New York).
Frequently Asked Questions
What is clinical trial NCT06463028 about?
NCT06463028 is a clinical study titled "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer". This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
What is the current status of trial NCT06463028?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-12-12. Estimated completion is 2029-09.
What conditions does trial NCT06463028 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06463028?
The interventions under investigation include: Paclitaxel (DRUG), Sapanisertib (DRUG), Serabelisib (DRUG).
Who is sponsoring clinical trial NCT06463028?
This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06463028 being conducted?
This trial has 18 study locations across California, Florida, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06463028's enrollment target sits among peer trials
40 137th of 181 higher than 44 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI